As part of our series focussing on medicines in Australia, we have added a product review of the use of brexucabtagene autoleucel for relapsed or refractory mantle-cell lymphoma.
This review discusses indications and dosage, contraindications and a series of clinical studies featuring brexucabtagene autoleucel use. It provides commentary from Professor Michael Dickinson, the Disease Group Lead in Aggressive Lymphoma at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital.
Please login below to download this issue (PDF)